Billionaires Holding MGNX

BILLIONAIRE ALLOCATION SHARES OWNED (M) % CO AVG. COST RETURN

FUNDAMENTALS

  • N/A
    PE

  • 0.0
    Yield

  • 34.2M
    Shares Outstanding

  • 1.11B
    Market Cap

News & Insights

ABOUT

MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its propr...

Buffett's key to investing: Four stocks that show a durable competitive advantage

NEWS

Icahn Enterprises launches tender offer for Federal-Mogul shares at 5.6% discount

READ MORE